HOME >> BIOLOGY >> NEWS
Malaria drug may treat metabolic syndrome's many symptoms

A drug used for decades to treat and prevent malaria might also fight the many symptoms of metabolic syndrome, a potentially disabling condition that is estimated to affect as many as a quarter of American adults. The findings appear in the November 2006 issue of the journal Cell Metabolism, published by Cell Press.

Researchers, led by Clay F. Semenkovich of Washington University School of Medicine and Michael B. Kastan of St. Jude Children's Research Hospital, found in studies of mice that the antimalaria drug chloroquine improved symptoms of metabolic syndrome; the drug reduced atherosclerosis, lowered blood pressure, and improved blood sugar tolerance. Chloroquine works by activating a particular stress pathway that mediates susceptibility to the syndrome, they found.

"In animals, activating this pathway with extremely low doses of chloroquine counteracted many of the features of metabolic syndrome," said Semenkovich. Semenkovich said he expects to begin a clinical trial of the drug's utility for curbing metabolic syndrome in human patients very soon.

Often associated with insulin resistance, metabolic syndrome can include five components: high triglycerides, low "good" cholesterol, high blood pressure, high blood sugar, and central obesity--characterized in men by a pants waist size of 40 or greater, Semenkovich said. Patients who exhibit three of the five components fit the criteria for metabolic syndrome.

The condition is also associated with atherosclerosis, leaving patients at increased risk of death from cardiovascular disease, the researchers said.

Rather than representing "a unique entity," some have suggested that the metabolic syndrome may simply reflect the cumulative contribution of its components to atherosclerotic risk, the researchers said. An alternative view is that atherosclerosis, insulin resistance, and the component clinical features of the metabolic syndrome share a common unifying mechanism, t
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
7-Nov-2006


Page: 1 2 3

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. 20 Years of Malaria Research: Outcomes and Perspectives
8. Malaria poses additional risks for first-time mothers
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/22/2020)... ... July 21, 2020 , ... ... and innovation in technology and compliance, announces a new solution to manage regulated ... ensure every layer of their technology stack complies with FDA and global regulations. ...
(Date:7/4/2020)... ... 2020 , ... Aesthetics Biomedical (ABM), a leading aesthetics product ... only the products and treatments developed, but also the dedicated team behind the ... brands built by ABM have received several honors already for 2020, each of ...
(Date:6/28/2020)... Switzerland (PRWEB) , ... June ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that it ... company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... “We are ... Third Wave Bioactives. “It’s the only technology of its kind on the market and ... of onions with the protective capacity of traditional cultured ingredients, creating a natural way ...
(Date:7/18/2020)... ... 17, 2020 , ... dicentra , a leading Contract ... industries, is pleased to announce that Charles Galea has joined its clinical trials ... is an accomplished and results-driven sales executive with over 10 years of expertise ...
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
(Date:7/10/2020)... ... 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will ... SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at the ...
Breaking Biology Technology:
Cached News: